Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Br J Haematol. 2020 May;189(3):e104-e108. doi: 10.1111/bjh.16515. Epub 2020 Mar 3.

Authors

Guadalupe Antelo¹, Abhishek A Mangaonkar¹, Giacomo Coltro¹, Ajinkya Buradkar¹, Terra L Lasho¹, Christy Finke¹, Ryan Carr¹, Moritz Binder¹, Naseema Gangat¹, Aref Al-Kali¹, Michelle A Elliott¹, Rebecca L King², Matthew Howard², Megan E Melody³, William Hogan¹, Mark R Litzow¹, Ayalew Tefferi¹, Martin E Fernandez-Zapico⁴, Rami Komrokji³, Mrinal M Patnaik¹

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
³ Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
⁴ Division of Oncology Research, Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

PMID: 32128785
DOI: 10.1111/bjh.16515

No abstract available

Keywords: ESA; MDS-RS; MDS/MPN-RS-T; erythropoiesis stimulating agents; myeloid leukaemia; sideroblastic anaemia.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anemia, Sideroblastic*
Erythropoiesis
Hematinics*
Humans
Leukemia*
Neoplasms*
Thrombocytosis*
World Health Organization

Substances

Hematinics

Grants and funding